Download Docs
Export

ADVANZ

97671247 | Trademark

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed Nov. 10, 2022
Serial No. 97671247
Examining Attorney ABIGAIL SUE
Class A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations; 005; 006; 018; 044; 046; 051; 052; 026; 039; 044
ADVANZ
Status An appeal of a final refusal to register the mark is pending before the Trademark Trial and Appeal Board. For further information, see TTABVUE on the Trademark Trial and Appeal Board web page.
Opposition 97671247
In re Mercury Pharma Group Limited
  • Mercury Pharma Group Limited;
Last Updated: 6 months, 1 week ago
Filing Date # Docket Text